Physician profile
Amee Mehta
NPI 1306133376
$3,214.98
in general payments reported to CMS, 2019-2025
20 companies · $96.45 in 2025
The $96.45 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.55 · 2021: $560 · 2022: $893 · 2023: $1,638 · 2024: $15.54 · 2025: $96.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,660 · Education: $89.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,659.95 |
| Education | $89.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $966.65 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $662.60 | 2022-2025 | |
| Lilly USA, LLC | $645.41 | 2022-2023 | Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $264.38 | 2021-2022 | |
| Glaxosmithkline, LLC. | $108.67 | 2023 | Arexvy, Shingrix |
| Pfizer INC. | $105.55 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $98.95 | 2023 | Farxiga |
| Amgen INC. | $81.98 | 2021-2023 | Repatha, Otezla |
| Exact Sciences Corporation | $50.77 | 2023 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $41.05 | 2023-2025 | Nexletol, Contrave |
| Astellas Pharma US INC | $24.13 | 2023 | Veozah |
| Almatica Pharma LLC | $23.60 | 2023 | Gralise, Loreev Xr |
| Sobi, INC | $23.29 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $21.37 | 2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $21.02 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $16.79 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.45 | 2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.48 | 2023 | |
| Kaleo, INC. | $14.29 | 2022 | |
| Boston Scientific Corporation | $12.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amee Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.